Table 2.
Diagnostic accuracy of interpretation of CLE biopsies by reviewer.
| FNa Dosing Group | P value | |||
|---|---|---|---|---|
| Redose, n=12 | Initial dose, n=18 | Single dose, n=19 | ||
| Mean timing, min* | 6.4 ± 3.8 | 93.9 ± 50.1 | 123.2 ± 35.9 | |
| Diagnostic accuracy, no. (%) | ||||
| Experienced neuropathologist | 10 (83) | 13 (72) | 9 (47) | 0.03 |
| Experienced neurosurgeon | 10 (83) | 13 (72) | 9 (47) | 0.03 |
| Experienced neurosurgeon | 10 (83) | 13 (72) | 9 (47) | 0.03 |
| Inexperienced neurosurgeon | 10 (83) | 7 (39) | 10 (53) | 0.2 |
| Inexperienced neurosurgeon | 10 (83) | 14 (78) | 11 (58) | 0.1 |
| Inexperienced non-neurosurgeon | 10 (83) | 10 (56) | 12 (63) | 0.3 |
| Inexperienced non-neurosurgeon | 10 (83) | 11 (61) | 12 (63) | 0.3 |
CLE, confocal laser endomicroscopy; FNa, fluorescein sodium.
*Mean timing of CLE biopsy imaging after FNa administration.